CRISPR, Vertex Get FDA OK of Casgevy Gene Therapy in Sickle-Cell Disease
By Colin Kellaher
CRISPR Therapeutics and Vertex Pharmaceuticals have won Food and Drug Administration approval of their Casgevy gene therapy for sickle-cell disease, marking the first U.S. green light for a drug using the gene-editing technology known as Crispr.
The FDA on Friday said the approval covers Casgevy for the treatment of sickle-cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises
U.K. regulators last month gave the world's first approval of Casgevy, granting conditional marketing authorization for the treatment of sickle-cell disease and transfusion-dependent beta thalassemia, a pair of inherited blood disorders.
An FDA decision on Casgevy in transfusion-dependent beta thalassemia is due by the end of March.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 08, 2023 11:31 ET (16:31 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
What I Hope My 14-Year-Old Learned at Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Amazon Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Dividend Stocks
-
3 Stocks With High Dividend Yields That Warren Buffett Likes
-
How to Invest Like Warren Buffett
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?